Research programme: chronic obstructive pulmonary disease therapeutics - Dr. Reddy's Laboratories/Pulmagen Therapeutics

Drug Profile

Research programme: chronic obstructive pulmonary disease therapeutics - Dr. Reddy's Laboratories/Pulmagen Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argenta Discovery; Dr Reddys Laboratories
  • Developer Dr Reddys Laboratories; Pulmagen Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
  • 02 Feb 2010 Argenta Discovery has been acquired by Galapagos NV
  • 27 Nov 2007 The first candidate drug to proceed into preclinical development has been selected from this programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top